Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study
In conclusion, in addition to the known anti-cancer benefits of adjuvant zoledronate, there are likely to be positive, lasting benefits in BMD and bone turnover.PMID:38630878 | DOI:10.1093/jbmr/zjad006 (Source: Cancer Control)
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Janet Brown Margaret A Paggiosi Emma Rathbone Walter Gregory Gian Bertelli Omar Din Eugene McCloskey David Dodwell David Cameron Richard Eastell Robert Coleman Source Type: research
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Blood Cancer Journal, Published online: 15 April 2024; doi:10.1038/s41408-024-01046-2In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 15, 2024 Category: Hematology Authors: Thomas Lund Michael Tveden Gundesen Annette Juul Vangsted Carsten Helleberg Einar Hauk ås Trine Silkj ær Jon Thor Asmussen Elena Manuela Teodorescu Bo Amdi Jensen Tobias Schmidt Sl ørdahl Hareth Nahi Anders Waage Niels Abildgaard Fredrik Schjesvold Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
CONCLUSION: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.PMID:38594593 | DOI:10.1007/s00432-024-05663-z (Source: Cell Research)
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Andrey Soares Fernando Sabino Marques Monteiro Karine Martins da Trindade Adriano Gon çalves E Silva Ana Paula Garcia Cardoso Andr é Deeke Sasse Andr é P Fay Andr é Paternò Castello Dias Carneiro Antonio Machado Alencar Junior Augusto C ésar de Andr Source Type: research
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
ConclusionImmunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - April 9, 2024 Category: Cancer & Oncology Source Type: research
Ex vivo expansion and activation of V γ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
Int J Hematol. 2024 Apr 6. doi: 10.1007/s12185-024-03763-7. Online ahead of print.ABSTRACTAs multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-genera...
Source: International Journal of Hematology - April 6, 2024 Category: Hematology Authors: Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Source Type: research
Ex vivo expansion and activation of V γ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
Int J Hematol. 2024 Apr 6. doi: 10.1007/s12185-024-03763-7. Online ahead of print.ABSTRACTAs multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-genera...
Source: International Journal of Hematology - April 6, 2024 Category: Hematology Authors: Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Source Type: research
Ex vivo expansion and activation of V γ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
Int J Hematol. 2024 Apr 6. doi: 10.1007/s12185-024-03763-7. Online ahead of print.ABSTRACTAs multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-genera...
Source: International Journal of Hematology - April 6, 2024 Category: Hematology Authors: Yusuke Inoue Asuka Oda Yusaku Maeda Ryohei Sumitani Masahiro Oura Kimiko Sogabe Tomoko Maruhashi Mamiko Takahashi Shiro Fujii Shingen Nakamura Hirokazu Miki Masahiro Hiasa Jumpei Teramachi Takeshi Harada Masahiro Abe Source Type: research
GSE263181 Exercise-induced beta2 adrenergic receptor activation enhances the anti-leukemic activity of expanded gamma-delta T-Cells via DNAM-1 upregulation and PVR-Nectin-2 recognition
Contributors : Forrest L Baker ; Kyle A Smith ; Preetesh L Mylabathula ; Tiffany M Zuniga ; Douglass M Diak ; Helena Batatinha ; Grace M Niemiro ; Michael D Seckeler ; Charles R Pedlar ; Danie P O'Connor ; Jamie Colombo ; Emmanual Katsanis ; Richard J SimpsonSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensExercise mobilizes cytotoxic lymphocytes to blood which may allow superior cell products to be manufactured for cancer therapy. Gamma-delta T-cells have shown promise for treating solid tumors, but there is a need to increase their potency against hematologic malignancies. Here, w...
Source: GEO: Gene Expression Omnibus - April 4, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena
ConclusionIn our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implement ation. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - April 2, 2024 Category: Orthopaedics Source Type: research
The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena
ConclusionIn our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implement ation. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - April 2, 2024 Category: Orthopaedics Source Type: research
Long-term effectiveness of zoledronic acid in patients with Paget ’s disease of bone – a retrospective cohort study
ConclusionThe majority of patients with PDB experience a mild disease course, marked by monostotic involvement and a low prevalence of fractures. Zoledronic acid effectively manages PDB, providing sustained biochemical response. The necessity for multiple zoledronic acid injections remains questionable, often implemented due to osteoporosis. (Source: Endocrine)
Source: Endocrine - March 30, 2024 Category: Endocrinology Source Type: research
